Sinovac Biotech Granted Continued Listing on Nasdaq Following Hearings Panel Decision
ByAinvest
Thursday, Jan 22, 2026 6:02 am ET1min read
SVA--
Sinovac Biotech has been granted continued listing on the Nasdaq Stock Market by the Nasdaq Hearings Panel, subject to completing its financial audit and remediation of filing delinquencies by May 11, 2026. The company must demonstrate compliance with Nasdaq Listing Rules by filing its annual report for 2024 on Form 20-F and an interim balance sheet and income statement for Q2 2025 on Form 6-K. Sinovac is working with its new auditor, Zhonghua, to complete the required audit procedures and regain compliance.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet